Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K
about
NVP-LDE225, a potent and selective SMOOTHENED antagonist reduces melanoma growth in vitro and in vivoThe anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signalingB-Raf and the inhibitors: from bench to bedsideTests to assist in the diagnosis of cutaneous melanoma in adults: a generic protocolSurvival in BRAF V600-mutant advanced melanoma treated with vemurafenibThe Ras-ERK and PI3K-mTOR pathways: cross-talk and compensationImproved survival with vemurafenib in melanoma with BRAF V600E mutationCombined BRAF and MEK inhibition in melanoma with BRAF V600 mutationsThe evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinibThe Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin CancerMEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapyMelanoma: oncogenic drivers and the immune systemTherapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune TherapyMultiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic TargetsImmune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With ImmunotherapyTargeting melanoma by small molecules: challenges aheadThe GIST of targeted therapy for malignant melanomaToward a Molecular Classification of Colorectal Cancer: The Role of BRAFEvasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds.Emerging targeted therapies for melanoma treatment (review)Modulation of insulin-like growth factor-1 receptor and its signaling network for the treatment of cancer: current status and future perspectivesThe dynamic nature of the kinomeMelanoma: new insights and new therapiesPathways and therapeutic targets in melanomaTargeting cancer with kinase inhibitorsNew treatments for metastatic melanomaResistance to BRAF inhibitors: unraveling mechanisms and future treatment optionsMelanoma: from mutations to medicineTargeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyondLandscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination TreatmentImpact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotypeTargeting the RAS oncogene.Cancer genome sequencing: understanding malignancy as a disease of the genome, its conformation, and its evolution.Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAFV600E ConformationDissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.Elucidating distinct roles for NF1 in melanomagenesis
P2860
Q21132689-1109647F-89C2-45E2-B5C0-7EA801C921FEQ21133611-7B54BF0D-4441-4B00-B958-88FF027024F9Q21198860-D4313911-6F03-480E-96EE-EC79CD9C0143Q24186719-70B8BF89-D3B0-4F03-AE84-02223A514004Q24594790-6C571CB7-696B-4C84-9A06-E9469DCFF34FQ24616946-020BA5C3-88DF-49EC-A0DB-42A2A3E24806Q24631953-CE24A65D-E5B2-45BE-85E1-013831D1E77EQ24632064-F9F03EE3-D1AE-4149-BDF4-0888F9F987AEQ26744335-420D0B16-CC2B-4C6E-8C84-7626A4DA1FC1Q26747247-E436ECC0-C5D2-4554-8556-890A3259BFF1Q26771192-03A443AB-1FD3-419A-8008-B5D20CD07958Q26775598-99A714E5-9C57-487B-8B8D-AE139A080A6BQ26782222-B8EFB47E-9CEE-4CF6-8208-DC4FECD92E8FQ26783032-C454D843-3074-4FE2-84C5-6843487F6F19Q26795735-51B34802-F230-4D7D-AEC1-4A1BDD0E6462Q26796309-5C983D65-81CA-4556-A9BE-45474C9DDFBEQ26824642-21CD4FA6-1F4A-4CAD-B047-D664DE6B5F96Q26827092-8231FF92-580C-40A7-8BD0-D8EB7113E324Q26827212-50650E68-C012-4078-AAD8-24D1A1892CF6Q26827810-5CF20B05-EDD9-47E9-8E7A-8962E2BD5342Q26829997-CE35FDAB-D242-4000-BB4E-2EDD3A6C2AD1Q26852578-D62DCF8D-217E-4FF2-AD29-B2D35D92B0BFQ26852588-50F6D3FB-20A8-440B-8CA4-13861901C84FQ26853127-29FD1E17-D5F4-404D-9961-C6DD13A489DFQ26865736-28488D46-9558-41B9-B17B-E884DFF5B07DQ26865765-D7B4060C-1DEE-47E2-AFF4-CCC31CB60381Q27007068-04EBCF87-527A-45D3-AED2-7CDE9DF8DB36Q27023596-45B061A4-94B9-48F5-AB41-BBE7FD16FD53Q27024061-7EEE1F80-1C7A-4830-9A7F-786F5F641D29Q27026323-B80C65F4-0D82-4CB6-8800-4AAE28808382Q27313653-5FD4AD5A-D891-4AD8-B253-2AD5F5C6E280Q27334924-A24954AA-6DD5-4D52-932A-1C14A36C3B3DQ27687198-25764B2F-A485-4012-BC07-10CD9B021AA9Q27690285-1BB201CE-4D54-4B3B-96F9-45CC05D1652AQ27727954-318EDC1C-ED73-4DAE-9D65-27949F37FBB9Q27851628-BADD2F62-FFA5-40FF-ADE8-5C664AA94880Q27851674-786AFB1C-4C90-4577-B3D2-84B6F0173FDBQ27851698-0831F674-2640-4D55-9FAB-7AFF02AF9B7FQ27851801-3D543E09-7436-4A49-B102-264C6CABEB59Q27851952-DA41A19B-B9B8-48A3-9736-E17FB9CD4659
P2860
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Acquired resistance to BRAF in ...... otargeting MEK and IGF-1R/PI3K
@ast
Acquired resistance to BRAF in ...... otargeting MEK and IGF-1R/PI3K
@en
type
label
Acquired resistance to BRAF in ...... otargeting MEK and IGF-1R/PI3K
@ast
Acquired resistance to BRAF in ...... otargeting MEK and IGF-1R/PI3K
@en
prefLabel
Acquired resistance to BRAF in ...... otargeting MEK and IGF-1R/PI3K
@ast
Acquired resistance to BRAF in ...... otargeting MEK and IGF-1R/PI3K
@en
P2093
P2860
P3181
P1433
P1476
Acquired resistance to BRAF in ...... otargeting MEK and IGF-1R/PI3K
@en
P2093
Cipolla AK
D'Andrea K
Fukunaga-Kalabis M
Gimotty PA
Laquerre S
P2860
P304
P3181
P356
10.1016/J.CCR.2010.11.023
P407
P4510
P577
2010-12-14T00:00:00Z